What You Should Know:
– Monogram Health, a Nashville, TN-based kidney disease benefit management and care delivery company announced a $375M growth funding round that will drive the company’s continued rapid expansion as the leading solution for high-quality, in-home care for polychronic patients living with chronic kidney and end-stage renal disease in the U.S.
– Investors in the round include CVS Health, Cigna, Humana, Memorial Hermann Health System, SCAN, TPG Capital, Frist Cressey Ventures, Heritage Group, Pura Vida Investments and Norwest Venture Partners, among others. With this transaction, Monogram will now have access to over 30% of the U.S. Medicare Advantage population and support upwards of 40% of the U.S. population. Today’s announcement follows a series of significant partnerships, and a $180 million Series B funding round in 2021.
Personalized and Compassionate In-Home Care for Polychronic Patients
Monogram is focused exclusively on managing chronic kidney disease (CKD) and end-stage renal disease (ESRD) at home. The company partners with health plans to provide their members with an evidence-based renal care model of clinical managed services, including complex case and disease management, utilization management, and medication therapy management, to improve patient outcomes and quality of life while dramatically reducing costs for the health care system.
For the more than 37 million American adults living with chronic kidney disease, access to the type of specialized care that Monogram provides is critical. Monogram’s transformative, high-touch and in-home model is driven by the company’s extensive market-based teams of clinicians, led by physicians and nurse practitioners who are supported by registered nurses, social workers, pharmacists, and care management teams. These providers and clinical experts are further bolstered by utilization management teams that focus in and around hospitalizations and discharge management, personalizing the experience and care for Monogram patients in nearly 4,000 U.S. cities across 34 states.
Expansion Plans
Monogram plans to use the proceeds to continue to support the rapid and widespread deployment of the company’s innovative in-home kidney and polychronic care delivery model as well as its technology- driven array of evidence-based clinical services, which include complex case and disease management, utilization management, and medication therapy management.
This innovative model of care transforms the way health care is delivered for those with kidney disease as well as comorbid metabolic disorders and has been shown to dramatically improve patient outcomes and quality of life while reducing medical costs across the health care continuum, improving access and affordability for all.
Market Share
With its new strategic syndicate, Monogram’s investor base now serves over 30% of Medicare Advantage members nationwide and supports upwards of 40% of the U.S. population, uniquely positioning the company to serve those living with chronic kidney disease and their related metabolic disorders.
